Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25028298 | 0.86 | TSHR (0.43) | ALDH1A1METAP1TSHROPRM1 | |
| SCHEMBL24900916 | 0.85 | ALDH1A1 (0.44) | ALDH1A1METAP1TSHROPRM1 | |
| SCHEMBL21162269 | 0.83 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL21894315 | 0.83 | OPRM1 (0.32) | OPRM1 | |
| SCHEMBL6280011 | 0.83 | OPRM1 (0.52) | ALDH1A1OPRM1 | |
| SCHEMBL28803333 | 0.83 | ALDH1A1 (0.46) | ALDH1A1METAP1TSHROPRM1 | |
| SCHEMBL6285007 | 0.81 | OPRM1 (0.50) | ALDH1A1OPRM1 | |
| SCHEMBL22550783 | 0.81 | OPRM1 (0.31) | OPRM1 | |
| SCHEMBL15966459 | 0.80 | OPRM1 (0.42) | ALDH1A1METAP1TSHROPRM1 | |
| SCHEMBL21027578 | 0.80 | OPRM1 (0.48) | ALDH1A1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023066190-A1 | COMPOUNDS AND THEIR USES AS GPR183 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2023-04-27 | — | — | WO | disclosed |
| EP-3633380-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | Taiho Pharmaceutical Co., Ltd. (JP) | 2020-04-08 | — | — | EP | disclosed |
| EP-1301486-B1 | IMIDAZOLIDINONES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2009-07-01 | — | — | EP | disclosed |
| US-6919291-B2 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20040110631-A1 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110631-A1 | Fluorinated zwitterionic cocatalyst activators for olefin polymerization | FZD7, FOS, COG4 | ALDH1A1 3691/4885METAP1 3951/4885TSHR 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.